Michael Larbig

469 total citations
18 papers, 336 citations indexed

About

Michael Larbig is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Immunology and Allergy. According to data from OpenAlex, Michael Larbig has authored 18 papers receiving a total of 336 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 7 papers in Physiology and 3 papers in Immunology and Allergy. Recurrent topics in Michael Larbig's work include Chronic Obstructive Pulmonary Disease (COPD) Research (8 papers), Asthma and respiratory diseases (7 papers) and Respiratory and Cough-Related Research (3 papers). Michael Larbig is often cited by papers focused on Chronic Obstructive Pulmonary Disease (COPD) Research (8 papers), Asthma and respiratory diseases (7 papers) and Respiratory and Cough-Related Research (3 papers). Michael Larbig collaborates with scholars based in Switzerland, United Kingdom and United States. Michael Larbig's co-authors include Κonstantinos Κostikas, Francesco Patalano, Donald Banerji, Robert Fogel, Jadwiga A. Wedzicha, Stefan Frent, Kenneth R. Chapman, Pankaj Goyal, Tadhg Guerin and John R. Hurst and has published in prestigious journals such as The Journal of Immunology, American Journal of Respiratory and Critical Care Medicine and CHEST Journal.

In The Last Decade

Michael Larbig

17 papers receiving 331 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael Larbig Switzerland 8 260 246 32 28 16 18 336
Jussi Haanpää Finland 5 242 0.9× 275 1.1× 26 0.8× 30 1.1× 13 0.8× 8 331
Takao Mochimaru Japan 7 91 0.3× 126 0.5× 24 0.8× 41 1.5× 12 0.8× 12 183
Evangelia Fouka Greece 13 262 1.0× 246 1.0× 42 1.3× 51 1.8× 29 1.8× 39 382
Tuğba Arıkoğlu Türkiye 11 95 0.4× 148 0.6× 66 2.1× 30 1.1× 13 0.8× 37 293
Suyong Yun Kirby United States 7 161 0.6× 172 0.7× 28 0.9× 39 1.4× 5 0.3× 10 270
Xinni Xu Singapore 8 67 0.3× 69 0.3× 60 1.9× 16 0.6× 9 0.6× 25 245
Sabina Škrgat Slovenia 8 97 0.4× 92 0.4× 14 0.4× 21 0.8× 5 0.3× 21 160
Natalia Hernandez‐Pacheco Spain 10 79 0.3× 161 0.7× 18 0.6× 61 2.2× 22 1.4× 16 234
Kentaro Watai Japan 9 140 0.5× 205 0.8× 105 3.3× 24 0.9× 3 0.2× 34 310
Michael A. Ghebre United Kingdom 7 197 0.8× 207 0.8× 11 0.3× 53 1.9× 66 4.1× 12 329

Countries citing papers authored by Michael Larbig

Since Specialization
Citations

This map shows the geographic impact of Michael Larbig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Larbig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Larbig more than expected).

Fields of papers citing papers by Michael Larbig

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Larbig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Larbig. The network helps show where Michael Larbig may publish in the future.

Co-authorship network of co-authors of Michael Larbig

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Larbig. A scholar is included among the top collaborators of Michael Larbig based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Larbig. Michael Larbig is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Papi, Alberto, Renee D. Stapleton, Paul Shore, et al.. (2023). Efficacy and Safety of Garadacimab in Combination with Standard of Care Treatment in Patients with Severe COVID-19. Lung. 201(2). 159–170. 12 indexed citations
2.
Buhl, Roland, Liam G. Heaney, Michael Larbig, et al.. (2019). One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid-long-acting β2-agonist in UK primary care settings. Respiratory Medicine. 162. 105859–105859. 28 indexed citations
3.
Frent, Stefan, Kenneth R. Chapman, Michael Larbig, et al.. (2018). Capturing Exacerbations of Chronic Obstructive Pulmonary Disease with EXACT. A Subanalysis of FLAME. American Journal of Respiratory and Critical Care Medicine. 199(1). 43–51. 4 indexed citations
4.
Chapman, Kenneth R., John R. Hurst, Stefan Frent, et al.. (2018). Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial. American Journal of Respiratory and Critical Care Medicine. 198(3). 329–339. 171 indexed citations
5.
Anzueto, Antonio, Κonstantinos Κostikas, Karen Mezzi, et al.. (2018). Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study. Respiratory Research. 19(1). 121–121. 30 indexed citations
6.
Κatsaounou, Paraskevi, Mikaëla Odemyr, Anne Lindberg, et al.. (2018). Smoking and severe persistent asthma. PA1230–PA1230. 1 indexed citations
7.
Hurst, John R., Κonstantinos Κostikas, Kenneth R. Chapman, et al.. (2018). Persistent blood eosinophilia and COPD exacerbation risk after ICS withdrawal from triple therapy in the SUNSET study. OA5387–OA5387. 1 indexed citations
8.
Roche, Nicolás, Jadwiga A. Wedzicha, Francesco Patalano, et al.. (2017). COPD exacerbations significantly impact quality of life as measured by SGRQ-C total score: results from the FLAME study. OA1487–OA1487. 7 indexed citations
9.
Wedzicha, Jadwiga A., Francesco Patalano, Steven S. Shen, et al.. (2017). Early occurrence of any COPD exacerbation predicts further higher risk of moderate/severe exacerbations regardless of recording tool: the FLAME study. PA3254–PA3254. 1 indexed citations
10.
Κostikas, Κonstantinos, Steven S. Shen, Michael Larbig, et al.. (2017). Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) versus salmeterol/fluticasone (SFC): the FLAME study. PA3255–PA3255. 3 indexed citations
11.
Erpenbeck, Veit J., Eva Vets, Lien Gheyle, et al.. (2015). Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo‐Controlled Studies in Healthy Volunteers. Clinical Pharmacology in Drug Development. 5(4). 306–313. 22 indexed citations
12.
Mahler, Donald A., Michael Larbig, Francesco Patalano, Samopriyo Maitra, & Donald Banerji. (2015). Dual Bronchodilation With QVA149 Improves Dyspnea in Patients With Moderate-to-Severe COPD: Pooled Analysis From the FLIGHT1 and FLIGHT2 Studies. CHEST Journal. 148(4). 730A–730A. 1 indexed citations
13.
Jones, Paul, Michael Larbig, Samopriyo Maitra, Angel FowlerTaylor, & Donald Banerji. (2015). Analysis of Improvement in SGRQ Component Scores With QVA149: Pooled Data From the FLIGHT1 and FLIGHT2 Studies. CHEST Journal. 148(4). 722A–722A. 1 indexed citations
14.
Erpenbeck, Veit J., et al.. (2014). Efficacy and safety of 10 day treatment with the CRTh2 antagonist QAV680 evaluated in patients with allergic rhinitis in an environmental exposure chamber. European Respiratory Journal. 44(Suppl 58). P4075–P4075. 3 indexed citations
15.
Erpenbeck, Veit J., et al.. (2014). QAV680, cetirizine and their combination reduce nasal symptoms in patients with intermittent allergic rhinitis in an environmental exposure chamber. European Respiratory Journal. 44(Suppl 58). P4069–P4069. 2 indexed citations
16.
Erpenbeck, Veit J., et al.. (2014). Safety, tolerability and pharmacokinetics of an oral competitive reversible CRTh2 antagonist, QAW039, in healthy subjects. European Respiratory Journal. 44(Suppl 58). P4073–P4073. 3 indexed citations
17.
Larbig, Michael, Bernard Burtin, Laurent Martin, et al.. (2006). Facial thermography is a sensitive tool to determine antihistaminic activity: comparison of levocetirizine and fexofenadine. British Journal of Clinical Pharmacology. 62(2). 158–164. 16 indexed citations
18.
Weigt, Henning, Peter F. Mühlradt, Michael Larbig, Norbert Krug, & Armin Braun. (2004). The Toll-Like Receptor-2/6 Agonist Macrophage-Activating Lipopeptide-2 Cooperates with IFN-γ to Reverse the Th2 Skew in an In Vitro Allergy Model. The Journal of Immunology. 172(10). 6080–6086. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jussi Haanpää Breakdown of academic impact, for papers by Takao Mochimaru Breakdown of academic impact, for papers by Evangelia Fouka Breakdown of academic impact, for papers by Tuğba Arıkoğlu Breakdown of academic impact, for papers by Suyong Yun Kirby Breakdown of academic impact, for papers by Xinni Xu Breakdown of academic impact, for papers by Sabina Škrgat Breakdown of academic impact, for papers by Natalia Hernandez‐Pacheco Breakdown of academic impact, for papers by Kentaro Watai Breakdown of academic impact, for papers by Michael A. Ghebre
Rankless by CCL
2026